Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid + diphtheria toxoid
- Development stage
- Phase 3
- Lead developer
- IBSS Biomed
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Clodivac is a bivalent booster vaccine developed by IBSS Biomed S.A. for active immunization against tetanus and diphtheria in adults. It consists of purified tetanus toxoid and a reduced dose of purified diphtheria toxoid, both adsorbed onto aluminum hydroxide to enhance immunogenicity. The vaccine works by stimulating the production of specific antitoxins that neutralize the toxins produced by *Clostridium tetani* and *Corynebacterium diphtheriae*. It is typically administered as a booster dose to maintain long-term immunity in individuals previously vaccinated with a primary series. Clinical trials have evaluated its safety and immunogenicity compared to other established Td vaccines.
- Brand names
- Clodivac
- Other names
- Td vaccineAdsorbed tetanus and diphtheria vaccine
02
Targets
TT (Tetanus toxoid)Diphtheria toxin
Beyond the preview
Go deeper on tetanus toxoid + diphtheria toxoid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid + diphtheria toxoid.